Gold (GLD) futures jumped nearly $40/oz. to log their biggest one-day gain of the year, supported by physical demand, prospects for easier global monetary policies and a weaker U.S. dollar. Today's rally brings gold's recovery to ~50% of losses from the selloff that began ~$1,560. Silver (SLV) enjoyed an even bigger bounce, rising 5.7%, but it needs a lot of catching up to approach historical gold/silver ratios. [View news story]
I just bought 2 pounds of GLD. Consider it A big gamble at this point since it could drop to about $1250/Oz. now I'm hopin'and a- prayin'.
Abbott Laboratories (ABT) declares $0.14/share quarterly dividend, in line with previous. Forward yield 1.60%. For shareholders of record Apr. 15. Payable May 15. Ex-div date Apr.11. (PR) [View news story]
I ca't figure out what's happening with the dividends anymore. Is the combined dividend from both Abt and Abbv equal to the former 3.3% of Abt?
Abbott Laboratories (ABT) declares quarterly dividend of $0.14/share post-split. The AbbVie board intends to declare dividend of $0.40/share totaling dividend to $0.54/share, 6% increase from prior dividend of $0.51, representing an annual yield of 3.31%. The quarterly dividend of $0.14/share will be payable on Feb. 15, to shareholders on record of Jan. 15. (PR) [View news story]
According to Warren Buffett, his company should be able to invest for it's shareholders better than they could individually for themselves. That is why they don't do dividends, but rather re-invest with share buy-backs instead.
IMO, the disparity of dividends may reflect some of that thinking. But the report is correct in that the dividend for the two split companies will total $0.54 (.14 + .40) as stated. Abbvie's strong income (largely from Humira) provides better margins than the typical product of the new Abt.
Anywho, the whole thing is intended to leave shareholders about where we were---and whether this is a great move for us will not be answered until there is time to see the eventual results of the split.
Abbott (ABT) says the SEC has declared effective the Form 10 Registration Statement filed by AbbVie, its research-based pharmaceuticals business, clearing the way to spin the company out. Abbott expects to complete the separation of AbbVie on January 1, 2013, whereupon the special dividend, declared on November 28, will be distributed. [View news story]
As a retiree of 15 years after 28 years with Abbott I have mixed feelings about this split. The company wasn't so large that a strong management team couldn't continue successfully. But then I felt the same way a few years ago when the hospital products groups were spun off. Until Abt matched the bigs in the business the split-offs just didn't seem necessary---unless Miles and his team just can't handle the growth and diversification. Apparently the board felt the various groups would be better managed after this move. That's unfortunate IMO.
Citi is out with its latest investment screen selecting U.S.-based dividend-paying stocks of companies that also earn approval in the credit markets. Three newcomers make the list - MRK, PFE, PGN - plus a dozen holdovers: MO, AEP, T, BMY, COP, ED, D, DUK, LLY, LMT, SO, VZ. [View news story]
Another Reason To Be Long AbbVie When Abbott Splits In Two [View article]
After Abt's last break-up ( spun off the hospital products group) both fared well in a move that I had thought would be disastrous, both did well. So I've ratcheted up my holdings this year and already had excellent gains even before the final action takes place. AbbVie will certainly be strong with the new drug that sounds like it can't miss.
Abbott (ABT +3.4%) moves up after initial results from its "Aviator" Phase 2b study of its interferon-free, investigational regimen for the treatment of hepatitis C indicated that 99% of the "treatment naive" HCV patients - those who had never been previously treated for the virus - showed a sustained virological response. Additionally, 93% of patients in the study who had previously been unsuccessfully treated for HCV also showed sustained virological response. [View news story]
As a retired Abt employee of 28 years, my life and financial fortunes are closely tied to Abbott stock since it is a large portion of my IRA. These stats sound so convincing, certainly enough to give the stock a good boost before the upcoming split-up of the company. Abbott is a great place to work as well as a solid, decent dividend company for its investors.
Gold (GLD) futures jumped nearly $40/oz. to log their biggest one-day gain of the year, supported by physical demand, prospects for easier global monetary policies and a weaker U.S. dollar. Today's rally brings gold's recovery to ~50% of losses from the selloff that began ~$1,560. Silver (SLV) enjoyed an even bigger bounce, rising 5.7%, but it needs a lot of catching up to approach historical gold/silver ratios. [View news story]
Abbott Laboratories (ABT) declares $0.14/share quarterly dividend, in line with previous. Forward yield 1.60%. For shareholders of record Apr. 15. Payable May 15. Ex-div date Apr.11. (PR) [View news story]
Abbott Laboratories (ABT) declares quarterly dividend of $0.14/share post-split. The AbbVie board intends to declare dividend of $0.40/share totaling dividend to $0.54/share, 6% increase from prior dividend of $0.51, representing an annual yield of 3.31%. The quarterly dividend of $0.14/share will be payable on Feb. 15, to shareholders on record of Jan. 15. (PR) [View news story]
IMO, the disparity of dividends may reflect some of that thinking. But the report is correct in that the dividend for the two split companies will total $0.54 (.14 + .40) as stated. Abbvie's strong income (largely from Humira) provides better margins than the typical product of the new Abt.
Anywho, the whole thing is intended to leave shareholders about where we were---and whether this is a great move for us will not be answered until there is time to see the eventual results of the split.
Abbott (ABT) says the SEC has declared effective the Form 10 Registration Statement filed by AbbVie, its research-based pharmaceuticals business, clearing the way to spin the company out. Abbott expects to complete the separation of AbbVie on January 1, 2013, whereupon the special dividend, declared on November 28, will be distributed. [View news story]
Citi is out with its latest investment screen selecting U.S.-based dividend-paying stocks of companies that also earn approval in the credit markets. Three newcomers make the list - MRK, PFE, PGN - plus a dozen holdovers: MO, AEP, T, BMY, COP, ED, D, DUK, LLY, LMT, SO, VZ. [View news story]
Another Reason To Be Long AbbVie When Abbott Splits In Two [View article]
Abbott (ABT +3.4%) moves up after initial results from its "Aviator" Phase 2b study of its interferon-free, investigational regimen for the treatment of hepatitis C indicated that 99% of the "treatment naive" HCV patients - those who had never been previously treated for the virus - showed a sustained virological response. Additionally, 93% of patients in the study who had previously been unsuccessfully treated for HCV also showed sustained virological response. [View news story]